Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers T > Headlines for Theravance Inc. > News item |
Theravance maintained at buy by Merrill
Theravance Inc. was kept at buy by Merrill Lynch analyst Eric Ende after the company report a third-quarter earnings per share loss of $0.63, which was modestly better than expected due to lower-than-expected operating expenses. The company remains on track to file an NDA in the fourth quarter for telavancin to treat serious skin infections. Shares of the South San Francisco, Calif.-based biopharmaceutical company were up $1.84, or 5.97%, at $32.66. (Nasdaq: THRX)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.